Heart failure & cardiomyopathies
Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 Left Ventricular Assist Device (LVAD) and Heart Transplant Using MOMENTUM 3 and UNOS Registry
Authors' conclusion
Contemporary data suggest that durable LVAD therapy may offer survival outcomes comparable to HT in adults <50 years of age.
Study context
- Population
- Patients 18–49 years of age with advanced heart failure (HF), 2014–2018
- Participants
- 420 / 1,955 / 1,176
- Exposure
- HM3 LVAD vs heart transplantation (HT)
- HM3n = 420
- HT listingn = 1,955reference
- HT recipientsn = 1,176reference
Methodological detailspropensity-score matched
- Propensity-score matched
Main finding
2-year survival from treatment · 2 years
Hazard ratio
1.18
P = 0.53
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HM3 | HT listing | HT recipients | HR | P value | |
|---|---|---|---|---|---|---|
| Freedom from death (HM3) vs freedom from death or delisting for deterioration (HT listing), from implantation or listing | 90.1% | 76.7% | Not reported in the abstract | 0.38 | P < 0.0001 | HT recipients: not reported in the abstract |
Safety
| Outcome | HM3 | HT listing | HT recipients | P value | |
|---|---|---|---|---|---|
| Renal dysfunction requiring dialysis · 1 year | 5.0% | Not reported in the abstract | 10.4% | P = 0.016 | HT listing: not reported in the abstract |
| Infection-related hospitalizations · 1 year | 24.8% | Not reported in the abstract | 34.2% | P = 0.012 | HT listing: not reported in the abstract |
| Debilitating stroke · 1 year | 3.4% | Not reported in the abstract | 0.3% | P = 0.027 | HT listing: not reported in the abstract |
Original publication
Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry. JACC Heart Fail. Published 7 February 2026. doi:10.
Summarised from the published abstract; every number is checked against it